Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Zeneca's CysLT1 antagonist shows potential for once-daily dosing; efficacy studies warranted

Sep. 29, 1998

V-11294A: an orally active PDE4 inhibitor undergoes testing in healthy volunteers

Sep. 29, 1998

Shionogi describes new PGD2 antagonists for allergic and inflammatory disorders

Sep. 28, 1998

Phase III trials initiated for desloratadine

Sep. 24, 1998

Preclinical studies with YM-26818 indicate efficacy in ARDS, COPD

Sep. 23, 1998

Antiallergic and antiinflammatory agents developed at Takeda

Sep. 23, 1998

New from Banyu: M3-selective muscarinic antagonists with excellent activity, improved safety

Sep. 22, 1998

TAN-2474 compounds from Gliocladium act as complement inhibitors

Sep. 22, 1998

Infasurf product launch delayed again

Sep. 21, 1998

Sankyo patents series with dual NK1/NK2-antagonist activity

Sep. 21, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...